CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for Sickle Cell Disease Therapy
CorrectSequence Therapeutics, a biotechnology company, has announced promising results from a clinical trial involving its high-precision base-editing therapy, CS-206, for sickle cell disease (SCD). The therapy has shown efficacy in preventing vaso-occlusive crises (VOCs) and anemia in a patient for over 15 months post-treatment. CS-206 utilizes transformer Base Editing (tBE) technology to precisely edit the HBG1/2 promoter region in hematopoietic stem cells, increasing fetal hemoglobin levels and reducing sickle hemoglobin. This approach offers advantages over CRISPR-based therapies by avoiding DNA double-strand breaks, thus minimizing risks of genomic deletions and mutations. The therapy has demonstrated rapid hematopoietic recovery and significant reduction in red blood cell sickling. 
